# TDNA (T. Rowe Price Biotech ETF)

T. Rowe Price · Thematic ETFs · data as of Oct 2, 2026

TDNA has not filed its holdings yet, so there is nothing to look through.

## Key facts

- TDNA, total return, since launch: −3.6%, as of Oct 2, 2026.
- TDNA, expense ratio: 0.55% (485BPOS XBRL, Jul 24, 2026).

## TDNA over each window to Oct 2, 2026

| Window | Total return | S&P 500 | Gap to S&P 500 | Gap to Nasdaq-100 |
| --- | --- | --- | --- | --- |
| Since launch | −3.6% | +1.2% | −4.8 pts | −8.3 pts |

## Every published field

| Field | Value | Source |
| --- | --- | --- |
| Theme | Biotech | ETFIQ, editorial |
| Launched | Sep 17, 2026 | ETFIQ |
| Below its all-time high | −4.0% | ETFIQ |
| Expense ratio | 0.55% | 485BPOS XBRL, Jul 24, 2026 |

## Questions

### Has TDNA beaten the S&P 500?

Over the year to Oct 2, 2026 TDNA returned −3.6% with distributions reinvested, against +1.2% for the S&P 500, so it finished behind the index by 4.8 points.

### What does TDNA cost?

The prospectus expense ratio is 0.55% a year.


## Cite this page

ETFIQ, TDNA, data as of Oct 2, 2026. https://etfiq.com/funds/tdna
Free to use with attribution; the underlying files are at https://etfiq.com/data/.

HTML: https://etfiq.com/funds/tdna  ·  JSON: https://etfiq.com/funds/tdna.json